Last updated: March 13, 2026
What is the drug associated with NDC 24979-0199?
NDC 24979-0199 refers to Caspofungin Acetate for Injection. It is an antifungal medication used primarily to treat invasive fungal infections, including candidemia, esophageal candidiasis, and neutropenic fever with suspected fungal infections. The drug is marketed under the brand Cancidas by Merck & Co.
Market Size and Competitive Landscape
Global and U.S. Market
The global antifungal market was valued at approximately $4.8 billion in 2022 and is projected to grow at a compound annual growth rate (CAGR) of 4.2% through 2030 [1].
In the United States, the market for antifungal injections, including caspofungin, is estimated at $1.2 billion in 2022. The primary drivers include increased incidences of invasive fungal infections in immunocompromised populations and expanding indications for echinocandin antifungals [2].
Key Competitors
- Micafungin (Fungizone) – Also an echinocandin, with a similar spectrum.
- Anidulafungin (Eraxis) – Market share is growing due to its simplified dosing.
- Amphotericin B formulations – Older but still relevant in specific cases.
Market Share Dynamics
Caspofungin holds approximately 45% of the echinocandin segment, with micafungin at 35% and anidulafungin at 15% [3].
Price Trajectory and Trends
Current Pricing Landscape
- Price per vial (average): Approximately $1,200 to $1,500 for a 70 mg dose.
- Annual treatment cost: Estimated at $50,000 to $70,000 per patient, depending on treatment duration and dosing.
Historical Price Trends
From 2010 to 2022, the price of caspofungin experienced an increase of approximately 25%, driven by manufacturing costs and market demand. Price adjustments are linked to inflation, supply chain factors, and negotiated payor contracts.
Future Price Projections (2023-2028)
Based on current trends and market factors, the average price per vial is expected to increase by 2% to 4% annually, reaching roughly $1,250 to $1,560 by 2028.
Factors Influencing Future Prices
- Generic Entry: Limited, as caspofungin patents and exclusivity periods have expired or are nearing expiration in key markets.
- Manufacturing Costs: Slight increases due to supply chain inflation.
- Reimbursement Policies: Payor pressure may limit price hikes, favoring value-based pricing.
- Emerging Competition: The entrance of biosimilars or new antifungal agents could exert downward pressure.
Regulatory Landscape and Patent Status
Caspofungin was approved by the FDA in 2001. Merckholds exclusivity until 2024, after which generic versions could enter the market.
Any patent challenges or new formulations could influence pricing and market share. Patent cliffs could lead to significant price reductions, affecting revenue projections.
Strategic Implications for Stakeholders
- Manufacturers: Focus on operational efficiencies to maintain margins amid gradual price escalation.
- Researchers: Monitor emerging antifungal agents, especially oral formulations, which could replace injectable caspofungin.
- Investors: Consider potential revenue decline post-patent expiration and the impact of generics.
Key Takeaways
- The global antifungal market is growing steadily, with caspofungin as a leading injectable agent.
- U.S. market size is approximately $1.2 billion, with caspofungin holding nearly half of the echinocandin market.
- Current pricing stands at $1,200–$1,500 per vial; prices are projected to increase modestly at 2–4% annually through 2028.
- Patent expiration in 2024 could facilitate generic competition, putting downward pressure on prices.
- Industry competition and hospital formulary preferences shape future pricing and market share dynamics.
FAQs
Q1: How does the emergence of generics impact caspofungin prices?
A: Entry of generics post-patent expiration in 2024 is expected to cause significant price reductions, potentially decreasing market prices by 30–50% depending on competition intensity.
Q2: What are the primary drivers of increased antifungal drug prices?
A: Manufacturing costs, supply chain inflation, R&D investments, and demand in immunocompromised populations.
Q3: Are there major regulatory barriers affecting price projections?
A: Patent durations and exclusivity periods heavily influence pricing. No recent regulatory barriers have delayed generic approval post-patent expiry.
Q4: How do pricing trends compare internationally?
A: European markets generally price similar or higher than U.S., reflecting healthcare system differences. Price reductions are expected globally following patent expiry.
Q5: What is the outlook for innovative formulations of caspofungin?
A: Oral formulations and combination therapies are under development, which could influence injectable caspofungin’s market share and pricing.
References
[1] Research and Markets. (2023). Global Antifungal Market Size, Share & Trends Analysis Report.
[2] IQVIA. (2022). U.S. Antifungal Market Data.
[3] MarketWatch. (2022). Competitive Analysis of Echinocandin Drugs.
[4] FDA. (2022). Caspofungin (Cancidas) Approval and Labeling Information.
